The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The Emerging Risk of Peptides in Supplements LegitScript FDA Moves to Reevaluate Several Peptides American Med Spa Association